Literature DB >> 12933872

Protective mucosal Th2 immune response against Toxoplasma gondii by murine mesenteric lymph node dendritic cells.

Isabelle Dimier-Poisson1, Fleur Aline, Marie-Noëlle Mévélec, Céline Beauvillain, Dominique Buzoni-Gatel, Daniel Bout.   

Abstract

Toxoplasma gondii, an obligate intracellular parasite pathogen which initially invades the intestinal epithelium before disseminating throughout the body, may cause severe sequelae in fetuses and life-threatening neuropathy in immunocompromised patients. Immune protection is usually thought to be performed through a systemic Th1 response; considering the route of parasite entry it is important to study and characterize the local mucosal immune response to T. gondii. Despite considerable effort, Toxoplasma-targeted vaccines have proven to be elusive using conventional strategies. We report the use of mesenteric lymph node dendritic cells (MLNDCs) pulsed ex vivo with T. gondii antigens (TAg) as a novel investigation approach to vaccination against T. gondii-driven pathogenic processes. Using a murine model, we demonstrate in two genetically distinct mouse strains (C57BL/6 and CBA/J) that adoptively transferred TAg-pulsed MLNDCs elicit a mucosal Toxoplasma-specific Th2-biased immune response in vivo and confer strong protection against infection. We also observe that MLNDCs mostly traffic to the intestine where they enhance resistance by reduction in the mortality and in the number of brain cysts. Thus, ex vivo TAg-pulsed MLNDCs represent a powerful tool for the study of protective immunity to T. gondii, delivered through its natural route of entry. These findings might impact the design of vaccine strategies against other invasive microorganisms known to be delivered through digestive tract.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12933872      PMCID: PMC187296          DOI: 10.1128/IAI.71.9.5254-5265.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue.

Authors:  D N Cook; D M Prosser; R Forster; J Zhang; N A Kuklin; S J Abbondanzo; X D Niu; S C Chen; D J Manfra; M T Wiekowski; L M Sullivan; S R Smith; H B Greenberg; S K Narula; M Lipp; S A Lira
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii.

Authors:  G Yap; M Pesin; A Sher
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

Review 4.  Dendritic cells from different tissues induce production of different T cell cytokine profiles.

Authors:  M P Everson; D S McDuffie; D G Lemak; W J Koopman; J R McGhee; K W Beagley
Journal:  J Leukoc Biol       Date:  1996-04       Impact factor: 4.962

Review 5.  Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites.

Authors:  R T Gazzinelli; E Y Denkers; A Sher
Journal:  Infect Agents Dis       Date:  1993-06

6.  Mucosal and systemic cellular immune responses induced by Toxoplasma gondii antigens in cyst orally infected mice.

Authors:  T Chardès; F Velge-Roussel; P Mevelec; M N Mevelec; D Buzoni-Gatel; D Bout
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

7.  Pathophysiology of toxoplasmosis.

Authors:  J K Frenkel
Journal:  Parasitol Today       Date:  1988-10

8.  Peripheral deletion of antigen-reactive T cells in oral tolerance.

Authors:  Y Chen; J Inobe; R Marks; P Gonnella; V K Kuchroo; H L Weiner
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

9.  Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function.

Authors:  R A Daynes; B A Araneo; T A Dowell; K Huang; D Dudley
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells.

Authors:  A Iwasaki; B L Kelsall
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

View more
  11 in total

1.  Differential Gamma Interferon- and Tumor Necrosis Factor Alpha-Driven Cytokine Response Distinguishes Acute Infection of a Metatherian Host with Toxoplasma gondii and Neospora caninum.

Authors:  Shannon L Donahoe; David N Phalen; Bronwyn M McAllan; Denis O'Meally; Milton M McAllister; John Ellis; Jan Šlapeta
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

2.  Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.

Authors:  Valentina Martin; Alicia Supanitsky; Pablo C Echeverria; Silvana Litwin; Tamara Tanos; Adolfo R De Roodt; Eduardo A Guarnera; Sergio O Angel
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

3.  Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection.

Authors:  Fleur Aline; Daniel Bout; Sébastian Amigorena; Philippe Roingeard; Isabelle Dimier-Poisson
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

4.  A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models.

Authors:  Hayam Mohamed Ezz Eldin; Hanan Hussein Kamel; Abeer Fathy Badawy; Lobna Sadek Shash
Journal:  J Parasit Dis       Date:  2013-11-20

5.  Immunogenicity and protection efficacy of enhanced fitness recombinant Salmonella Typhi monovalent and bivalent vaccine strains against acute toxoplasmosis.

Authors:  Fei-Kean Loh; Sheila Nathan; Sek-Chuen Chow; Chee-Mun Fang
Journal:  Pathog Glob Health       Date:  2021-02-01       Impact factor: 2.894

6.  Evaluation of Immune Responses Induced by GRA7 and ROP2 Genes by DNA Vaccine Cocktails Against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Hossein Vazini; Fatemeh Ghafarifar; Zohreh Sharifi; Abdolhosein Dalimi
Journal:  Avicenna J Med Biotechnol       Date:  2018 Jan-Mar

7.  Targeted Delivery of Toxoplasma gondii Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis.

Authors:  Zineb Lakhrif; Alexis Moreau; Bruno Hérault; Anne Di-Tommaso; Matthieu Juste; Nathalie Moiré; Isabelle Dimier-Poisson; Marie-Noëlle Mévélec; Nicolas Aubrey
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

8.  Immune Mediator Profile in Aqueous Humor Differs in Patients with Primary Acquired Ocular Toxoplasmosis and Recurrent Acute Ocular Toxoplasmosis.

Authors:  Claudia Thieme; Stephan Schlickeiser; Sylvia Metzner; Claudia Dames; Uwe Pleyer
Journal:  Mediators Inflamm       Date:  2019-02-17       Impact factor: 4.711

9.  Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.

Authors:  Louis Lantier; Agathe Poupée-Beaugé; Anne di Tommaso; Céline Ducournau; Mathieu Epardaud; Zineb Lakhrif; Stéphanie Germon; Françoise Debierre-Grockiego; Marie-Noëlle Mévélec; Arthur Battistoni; Loïs Coënon; Nora Deluce-Kakwata-Nkor; Florence Velge-Roussel; Céline Beauvillain; Thomas Baranek; Gordon Scott Lee; Thibault Kervarrec; Antoine Touzé; Nathalie Moiré; Isabelle Dimier-Poisson
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

10.  MyD88 is crucial for the development of a protective CNS immune response to Toxoplasma gondii infection.

Authors:  Marbel Torres; Rachel Guiton; Sonia Lacroix-Lamandé; Bernhard Ryffel; Samuel Leman; Isabelle Dimier-Poisson
Journal:  J Neuroinflammation       Date:  2013-02-01       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.